Skip Navigation


Annals of Oncology Advance Access originally published online on June 1, 2006
Annals of Oncology 2006 17(8):1228-1233; doi:10.1093/annonc/mdl114
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/8/1228    most recent
mdl114v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (21)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Tubiana-Hulin, M.
Right arrow Articles by Rouëssé, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tubiana-Hulin, M.
Right arrow Articles by Rouëssé, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution

M. Tubiana-Hulin*, D. Stevens, S. Lasry, J. M. Guinebretière, L. Bouita, C. Cohen-Solal, P. Cherel and J. Rouëssé

From the departments of medical oncology, biostatistics, surgery, pathology, radiotherapy and radiology, Centre René Huguenin, Saint-Cloud, France

* Correspondence to: Dr M. Tubiana-Hulin, Centre René Huguenin, 35 rue Daily, 92210 Saint Cloud, France. Tel: +0-47-11-15-29; Fax: +01-47-11-15-83; E-mail: m.tubiana{at}stcloud-huguenin.org

Background: We compared the impact of neoadjuvant chemotherapy on pathologic response and outcome in operable invasive lobular breast carcinoma (ILC) and invasive ductal breast carcinoma (IDC).

Patients and methods: We extracted from our database all patients with pure invasive lobular (n = 118, 14%) or pure invasive ductal carcinomas (n = 742, 86%). Their treatment included neoadjuvant chemotherapy, adapted surgery, radiotherapy and adjuvant hormonal treatment.

Results: Compared with IDC, ILC presented with larger tumors (T3: 38.1% versus 21.4%, P = 0.0007), more N0 nodes status (55.9% versus 43.3%, P = 0.01), less inflammatory tumors (5.9% versus 11.8%, P = 0.01), more hormone receptor positivity (65.5% versus 38.8%), lower histological grade (P < 0.0001). Final surgery was a mastectomy in 70% of patients with ILC (34% were reoperated after initial partial mastectomy) and in 52% of IDC after 8% of reoperation (P = 0.006). A pathological complete response (pCR) was achieved in 1% of ILC and 9% of IDC (P = 0.002). The outcome at 60 months was significantly better for ILC, but histologic type was not an independent factor for survival in multivariate analysis.

Conclusions: ILC appeared less responsive to chemotherapy but presented a better outcome than IDC. While new information on biological features of ILC is needed, we consider that neoadjuvant endocrine therapy in hormone receptor-positive ILC may be a more adapted approach than neoadjuvant chemotherapy.

Key words: invasive lobular breast carcinoma, neoadjuvant chemotherapy, pathological response, survival


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
R. B. Riggins, J. P-J. Lan, U. Klimach, A. Zwart, L. R. Cavalli, B. R. Haddad, L. Chen, T. Gong, J. Xuan, S. P. Ethier, et al.
ERR{gamma} Mediates Tamoxifen Resistance in Novel Models of Invasive Lobular Breast Cancer
Cancer Res., November 1, 2008; 68(21): 8908 - 8917.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
G. von Minckwitz, S. Kummel, P. Vogel, C. Hanusch, H. Eidtmann, J. Hilfrich, B. Gerber, J. Huober, S. D. Costa, C. Jackisch, et al.
Intensified Neoadjuvant Chemotherapy in Early-Responding Breast Cancer: Phase III Randomized GeparTrio Study
J Natl Cancer Inst, April 16, 2008; 100(8): 552 - 562.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Kaufmann, G. von Minckwitz, H. D. Bear, A. Buzdar, P. McGale, H. Bonnefoi, M. Colleoni, C. Denkert, W. Eiermann, R. Jackesz, et al.
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006
Ann. Onc., December 1, 2007; 18(12): 1927 - 1934.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
N. Biglia, L. Mariani, L. Sgro, P. Mininanni, G. Moggio, and P. Sismondi
Increased incidence of lobular breast cancer in women treated with hormone replacement therapy: implications for diagnosis, surgical and medical treatment
Endocr. Relat. Cancer, September 1, 2007; 14(3): 549 - 567.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
C. Shimizu, M. Ando, T. Kouno, N. Katsumata, and Y. Fujiwara
Current Trends and Controversies over Pre-operative Chemotherapy for Women with Operable Breast Cancer
Jpn. J. Clin. Oncol., January 3, 2007; (2007) hyl122v1.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.